OBJECTIVES: Two 12-week, randomized, double-blind, parallel-group studies were performed to compare the efficacy and safety of once-and twice-daily dosing of fluticasone propionate (FP) in the treatment of mild to moderate asthma, considered to require the equivalent of either 200 or 500 µg of FP daily.
OBJECTIVES: Two 12-week, randomized, double-blind, parallel-group studies were performed to compare the efficacy and safety of once-and twice-daily dosing of fluticasone propionate (FP) in the treatment of mild to moderate asthma, considered to require the equivalent of either 200 or 500 µg of FP daily.
PATIENTS AND METHODS:
In study A, 461 patients with asthma received FP either 200 µg once daily or 100 µg twice daily. In study B, 443 patients with asthma received FP, either 500 µg once daily or 250 µg twice daily. RESULTS: In both studies, regardless of the treatment regimen to which patients were randomly assigned, small improvements over baseline were observed in morning peak expiratory flows (PEF)and forced expiratory volume in 1 s (FEV 1 ) following 12 weeks of treatment. In study A, the mean morning PEF improved by 2.4% and 4.3% (once daily versus twice daily, P=0.008). In study B, the mean morning PEF improvement was 0.2% and 3.7% (once daily versus twice daily, P<0.001). For both studies, the increases observed in FEV 1 were not significantly different between the two groups (P = not significant). The incidence of exacerbations of asthma and related events was 13% and 5%, respectively, in the patients with mild asthma for the once-daily group versus the twice-daily group; these exacerbations were 12% and 10%, respectively, in patients with moderate asthma. Otherwise, the incidence and types of adverse events were comparable for the two treatment regimens. Although twice-daily dosing demonstrated small but statistically significant improvements over once-daily dosing, patients of both groups generally maintained a good level of asthma control on both regimens according to current treatment guidelines. CONCLUSIONS: Twice-daily dosing of FP is more effective than once-daily dosing, although the latter can maintain asthma control in most patients.
I
nflammation is an important feature of the airways of patients with asthma, and inhaled corticosteroids (ICS) are recommended for patients who require regular use of an inhaled beta 2 -agonist to control asthma symptoms (1, 2) . However, patient compliance with preventive therapy is often poor, particularly in a long term illness such as asthma, thus compromising the effectiveness of treatment (3, 4) . One method of improving compliance is to simplify the dosing regimen by decreasing the number of times that the medication has to be taken each day. Improvements in compliance have been achieved by reducing dosing frequency from four times per day to twice per day, and further improvements in compliance may be achieved with once-daily dosing (5, 6) .
The evidence as to whether equivalent dosages of ICS given once-or twice-daily are equally effective is conflicting. Several studies of patients with stable asthma have found that once-daily ICS was as effective as half the dose given twice daily (7) (8) (9) (10) (11) (12) (13) . However, two studies have reported the twice-daily administration of ICS to be more effective in the control of asthma than once-daily administration (14, 15) , and Weiner et al (16) found that, over 12 months, better control was achieved using twice-daily than with once-daily therapy. The timing of the once-daily dose of ICS was thought to be important; afternoon or evening dosings were equally as effective as twice-daily dosing and more effective than morning dosing (9, 12) . This supports the concept that circadian rythms influence the manifestations of asthma and the response of asthma to therapy (17) .
Although the administration of ICS at the end of the day may better antagonize an increased airway responsiveness and inflammation occuring at night, it is not known whether a morning dosage may be sufficient to control asthma with a potent ICS while possibly further reducing the risk of systemic side effects.
Fluticasone propionate (FP) is a topically active, synthetic glucocorticosteroid that is usually prescribed twice daily for the treatment of asthma. The safety and efficacy of FP in a twice-daily dosing regimen have been established in numerous clinical trials (18) (19) (20) (21) (22) (23) (24) . FP may be a suitable drug for once-daily dosing because it is highly lipophilic; lipophilicity is an important property for an ICS because it increases both drug uptake and retention in tissues, thereby prolonging the duration of action (25) . The present study aimed to compare the clinical efficacy of FP administered in once-daily with that of twice-daily dosing regimens, and to examine their safety.
PATIENTS AND METHODS

Study design and treatment regimen:
Two separate, multicentre, randomized, double-blind, parallel-group studies examined the efficacy and safety of FP given once or twice daily in patients with mild (study A) or moderate (study B) asthma. The study protocols were approved by local ethics committees at each participating centre, and the patient's informed consent was obtained before being included in a study. The designs of the studies were identical. After a two-week run-in during which patients continued to take their usual asthma medication, patients entered a 12-week, double-blind treatment phase. All patients were required to stop their prestudy ICS medication at this time. In study A, patients with mild asthma were randomly assigned to receive either once-daily treatment (200 µg FP in the morning and placebo in the evening) or twice-daily treatment (100 µg FP in the morning and 100 µg FP in the evening). In study B, patients with moderate asthma received once-daily treatment (500 µg FP in the morning and placebo in the evening) or twice-daily treatment (250 µg in the morning and 250 µg in the evening). All patients attended the clinic on five occasions during the treatment period and two weeks after the completion of study treatment. Salbutamol was provided as relief medication during both run-in and treatment periods. Providing that the route, dose and frequency remained constant, the following asthma medications were permitted during the study: sodium cromoglycate, nedocromil sodium, ketotifen, methylxanthines, inhaled anticholinergics, long acting beta 2 -agonists and oral beta 2 -agonists. Intranasal corticosteroids for rhinitis, antifungal medication for oropharyngeal candidiasis and medications for other disorders, with the exception of systemic corticosteroids, were also permitted.
Patients were aged 12 years and over with a clinical history of mild (study A) or moderate (study B) asthma, as defined in the 1992 International Consensus Report on Diagnosis and Treatment of Asthma (26) , for at least the preceding 12 weeks. Study A patients had a forced expiratory volume in 1 s (FEV 1 ) between 70% and 90% of predicted normal values and had previously received no ICS or up to 500 µg/day beclomethasone dipropionate (BDP), budesonide (BUD) or flunisolide, or up to 200 µg/day FP. Study B patients had an FEV 1 between 60% and 90% that of the predicted normal value and had previously received at least 400 µg/day and up to 1200 µg/day BDP, BUD or flunisolide (600 µg/day of FP). All patients were required to have no changes in their asthma medication during the preceding four weeks, at least 15% reversibility of their FEV 1 15 mins after inhaling salbutamol (200 µg via a metered dose inhaler or 400 µg via Diskhaler) and the ability to withhold an inhaled short acting bronchodilator for a minimum of 4 h before each clinic visit. Patients were excluded if their asthma was unstable or they had recently received any corticosteroids other than by inhalation; they had had a respiratory tract infection or had required emergency room treatment in the preceding four weeks; they had a concurrent disease likely to interfere with the study; they had a history of hypersensitivity to ICS; or they were unable to use salbutamol on an 'as required' basis. Pregnant or lactating women were also excluded. Efficacy assessments: The primary efficacy parameter was morning peak expiratory flow (PEF), measured daily through weeks 1 to 12, with secondary variables being evening PEF, diurnal variation in PEF, percentage predicted morning and evening PEF, day-and night-time asthma symptom scores, number of days with total symptom score of less than 2, symptomatic bronchodilator use and lung function measurements taken at the clinic (PEF and FEV 1 ). PEF was measured using a mini-Wright peak flow meter. The best of three measurements was recorded in the diary card each morning and evening.
Symptom severity and bronchodilator use were recorded by the patients each day in a diary card. Daytime symptoms were rated on a scale of 0 to 5, where 0 = no symptoms and 5 = symptoms so severe that the patient could not work or perform normal daily activities. Night-time symptoms were rated on a scale of 0 to 4, where 0 = no symptoms and 4 = symptoms so severe that the patient did not sleep at all. Lung function measurements were performed at each of seven clinic visits (prestudy; end of run-in; after two, four, eight and 12 weeks of treatment; and after follow-up), and the highest of three PEF and FEV 1 values was recorded. Patients were asked to withhold short acting beta 2 -agonists for 4 h, long acting inhaled beta 2 -agonists for 12 h and oral beta 2 -agonists for 24 h before attending the clinic. Safety assessments: All adverse events were recorded throughout the study and their relationship to treatment assessed. In addition, physical examinations, vital signs, routine urinalysis, hematology and biochemistry, including serum cortisol measurements as a measure of hypothalamicpituitary-adrenal axis function were conducted at baseline and repeated at the end of the study. Patients were required to attend the laboratory between 8:00 and 10:00 (time indicated in patients' charts) for the measurement of these parameters. Asthma exacerbations were defined as an increase in asthma symptoms requiring a change in bronchial anti-inflammatory treatment. Data analysis: Data were analyzed using SAS ,version 6.08 (SAS Institute, Cary, North Carolina), on an intent-to-treat basis defined as all patients chosen randomly to receive treatment unless there was evidence that the study medication was not taken. For analysis, at least a baseline period measurement and one treatment period measurement were required.
All tests were carried out at the two-sided 5% level of significance. An equivalence test was carried out for the primary efficacy variable (mean morning PEF for weeks one to 12 of treatment) by comparing the 90% confidence interval for the difference between two treatments with the predefined equivalence interval (-15 L/min, 15 L/min). Based on an estimated within-patient residual standard deviation of 40 L/min, 364 patients (assigned randomly in each study) were required to afford 95% power for declaring equivalence for the intentto-treat analysis with a type I error of 5%.
Daily diary card data were summarized per patient by taking the mean over the treatment period for the following variables: morning and evening PEF; the diurnal variation in PEF (defined as the difference between the previous evening and next morning values); percentage predicted morning and evening PEF; and number of days with symptom scores of less than 2. An ANCOVA was performed on these variables using run-in baseline values as a covariate and adjusted for age, centre or country, and sex. An ANCOVA was also performed on the measurements of PEF and FEV 1 taken in the clinic, using baseline values as covariates.
Secondary efficacy measures of asthma symptoms and use of relief medication were presented as frequency distributions and compared using the Wilcoxon rank-sum test. The Hodges-Lehmann estimate for the difference between treatment medians of median daytime score and corresponding 90% confidence limits were calculated.
All patients randomly assigned to treatment were included in the safety analysis. Treatment groups were compared with respect to all most common adverse events and all predictable adverse events using Fisher's exact test (two-sided).
RESULTS
Study A enrolled 523 outpatients from 49 centres in eight countries. Of these, 461 patients were randomly assigned to treatment, 230 received FP 200 µg once daily and 231 received FP 100 µg twice daily. In study B, 507 outpatients were enrolled from 32 centres in Canada. Of these, 443 were randomly assigned to treatment -222 received FP 500 µg once daily and 221 received FP 250 µg twice daily. Because of a lack of adequate source data documentation, one centre in study B that had enrolled nine patients was excluded from the intent-to-treat population (434 patients, 217 in each treatment group). The two treatment groups in each study were comparable in terms of age, duration of asthma and other demographic variables (Table 1 ). In addition, the patients in the two treatment groups were balanced with respect to the degree of their asthma, as indicated by their prestudy predicted morning PEF, or their prestudy ICS dose (Table 1) . Pulmonary function tests: For patients with mild asthma, study A, mean morning PEF improved over the 12-week treatment period in both treatment groups compared with baseline. Mean morning PEF increased by 10.5 L/min with once-daily dosing, and 18.7 L/min with twice-daily dosing (Table 2 ) -a statistically significant difference in favour of twice-daily dosing (P=0.012). For patients with moderate asthma, study B, improvements over baseline were only seen in the FP twice-daily group (by 16.7 L/min), whereas mean morning PEF remained largely unchanged in the FP once-daily group (increase of 0.7 L/min) ( Table 2 ) -a statistically significant difference favouring FP twicedaily (P<0.001). However, for the patients with mild asthma, the 90% confidence interval for the treatment difference, FP twice daily minus once daily (-13.6 to -2.8) was contained in the equivalence interval. By contrast, for patients with moderate asthma, the 90% confidence interval (-20.5 to -11.1) was not contained in the equivalence interval, and the criteria for declaring equivalence was not met (Table 2) .
Mean evening PEF also improved over the course of each study. Overall improvements in mean evening PEF of 9.7 L/min with FP once daily compared with 13.2 L/min with FP twice daily were observed in patients with mild asthma. In patients with moderate asthma, improvements of 4.9 L/min with once-daily and 10.4 L/min with twice-daily FP dosing were seen (Table 2) ; the improvement seen with twice-daily dosing was significantly greater (P=0.032).
In patients with mild asthma, diurnal variation in PEF improved with both once-and twice-daily dosing. Compared with baseline, mean diurnal variation in PEF was reduced by 1.4 L/min and 4.9 L/min, for once-daily and twice-daily dosing, respectively; the improvement was significantly greater with twice-daily dosing (P<0.002) ( Table 2 ). In patients with moderate asthma, those receiving once-daily dosing experienced an increase in mean diurnal variation in PEF of 4.5 L/min compared with baseline, while those receiving twice-daily dosing experienced a reduction of 7.0 L/min. Again, the improvement was significantly greater with twice-daily dosing (P<0.001). Other improvements were also observed in both the mild and moderate asthma patient studies, with statistically significant differences in favour of twice-daily dosing, in mean percentage predicted morning PEF (P=0.008, mild asthma; P<0.001, moderate asthma) and clinic assessments of PEF (P=0.12, mild asthma; P=0.007, moderate asthma) ( Table 2 ). In patients with moderate asthma, 21% and 13% of patients with daily versus twicedaily dosing, respectively, occasionally had PEF below 85% of the run-in value more than three times in seven days.
Increases in FEV 1 compared with baseline were observed in each study with both treatment groups. However, there were no significant differences in increases between treatment groups (Table 2) . Symptoms and medication needs: The patients' symptoms were well controlled before they were randomly assigned to these studies, and the use of bronchodilators was infrequent. Nevertheless, improvements were observed with both treatments in each study (Table 3 ). In patients with mild asthma, there were no significant differences between FP once daily and FP twice daily in daytime and night-time symptom scores or the number of days that symptom scores were less than 2 (Table 3 ). In patients with moderate asthma, there were significant differences in favour of FP twice daily in daytime symptom scores (P=0.025), night-time symptom scores (P<0.001) and the number of days that symptom scores were less than 2 (P=0.005) ( Table 3) .
The improvements in asthma control during the trials were reflected in decreases in day-and night-time bronchodilator use (Table 4 ). The twice-daily patient groups demonstrated a greater decrease in both daytime and night-time bronchodilator use, although it was only significant in patients with moderate asthma for night-time use (P=0.003) ( Table 4) .
In patients with moderate asthma, the lower the baseline use of bronchodilators, the more similar the two treatments. Patients with a baseline use of three times per week or less had changes in mean morning PEF, compared with baseline, of 6.0 and 13 L/min for once-daily and twice-daily treatments, respectively, whereas for use greater than seven times per week, the changes were -2 and 17 L/min, respectively. Adverse events and safety parameters: The adverse event profile did not differ markedly between the two treatment groups. Furthermore, the types of events reported were not unexpected for this patient population. Ear, nose and throat disorders were most often reported as adverse events by patients in both treatment groups. Approximately 31% of patients in the mild asthma study group and 54% of patients in the moderate asthma study group reported these types of events. In the patients with mild asthma, the most commonly reported events included headache (12% and 15% for the once-daily and twice-daily groups, respectively) and upper respiratory tract infection (11% and 10% for the once-daily and twice-daily groups, respectively). Similarly, in the study of patients with moderate asthma, most commonly reported events included headache (34% and 33% for the once-daily and twice-daily groups, respectively) and upper respiratory tract infections (30% and 28% for the once-daily and twicedaily groups, respectively).
In the mild asthma study, hoarseness and/or dysphonia was the most frequently reported drug-related adverse event occurring in 2% and 5% of patients who received FP once daily and FP twice daily, respectively. In the moderate asthma study, hoarseness and/or dysphonia and throat irritation were the most frequently reported drug-related adverse events. Throat irritation was reported by 5% and 7% of patients, and hoarseness and/or dysphonia was reported by 1% and 5% of patients who received FP once daily and FP twice daily, respectively. No other drug-related events were reported by 5% or more of patients.
In both studies, the incidence of exacerbations of asthma and related events was higher in the once-daily group than in the twice-daily group -13% and 5%, respectively, in patients in the mild asthma study, and 12% and 10%, respectively, in patients in the moderate asthma study. As expected, the majority of withdrawals were because of asthma or related events. The incidence of withdrawals was higher in the oncedaily group: 19 patients withdrew because of adverse events (16 in the once-daily group and three in the twice-daily group) in the mild asthma study and 12 patients withdrew (seven in the once-daily group and five in the twice-daily group) in the study of patients with moderate asthma. There were no significant effects on vital signs, urinalysis, hematology or laboratory parameters, and biochemistry including serum cortisol measurements in either study. In the mild asthma study, geometric mean serum cortisol concentrations were 379 nmol/L and 383 nmol/L at baseline in the once-and twice-daily dosing groups, respectively, and 394 nmol/L and 400 nmol/L, respectively, at the study end; the baseline adjusted geometric mean ratio of treatments was 1.03 for both groups. In the moderate asthma study, the baseline geometric mean values were 345 nmol/L in the once-daily group and 341 nmol/L in the twice-daily group, and at study end, the values were 346 nmol/L and 353 nmol/L, respectively; the adjusted geometric mean ratio was 0.99.
DISCUSSION
The patients in both the mild and the moderate asthma studies were relatively well controlled before being randomly assigned to treatment groups; symptom scores and use of bronchodilators were low. Patients with mild asthma had been receiving or up to 500 µg/day BDP or BUD, and patients with moderate asthma, 400 up to 1200 µg/day BDP or BUD. In both mild and moderate asthma studies, for a number of parameters, greater improvements were observed with twice-daily than with once-daily treatments. Although greater reductions in mean diurnal variation in PEF were observed with twice-daily dosing, a good level of asthma control was maintained throughout the 12-week treatment period in both the mild and moderate asthma studies, regardless of the treatment regimen (2) . For the PEF changes, a good level of control has been defined as a diurnal variation in PEF of less than 10% on five of seven days (2) . Accordingly, the mean diurnal variation in PEF observed in the mild asthma study averaged 3.3% and 2.1% for once-and twice-daily dosing, respectively, and in the moderate asthma study, averaged 4.2% and 2.0%, respectively.
Small differences in efficacy were observed between once-daily and twice-daily administration of FP in patients with mild asthma. Within the moderate asthma group, the fewer the asthma symptoms or the lower the baseline use of bronchodilators, the more similar the efficacy of once-and twice-daily treatments of FP. These observations support those of others (10) that once-daily ICS may be more suitable for use in stable, well controlled asthma. Some patients with asthma seem to show an increase in airway inflammatory features at night, and it is possible that these patients may benefit from twice-daily dosing. Alternatively, although this remains to be confirmed by further studies, because it has been suggested that the time of administration of corticosteroids may influence their efficacy (27) , the beneficial effect of corticosteroids on this nocturnal process may be optimized by late afternoon administration (9, 12, 27) .
In the present study, the once-daily dose was administered in the morning, and it is possible that the difference in efficacy between twice-daily and once-daily dosing may have been reduced if the once-daily dose had been given at the end of the day. However, the present study aimed to determine whether a single morning dose of a potent ICS was sufficient to keep asthma controlled while possibly further reducing the risk of systemic effects.
In accordance with current guidelines, it may be appropriate for the daily dose to be given just once per day during periods of good asthma control but split into two doses when features of poor control are noted, in addition to increasing the total daily dose according to the degree of loss of asthma control. Similarly, we may hypothesize that twice-daily administration may be more appropriate during periods of increased allergen exposure or at the onset of a respiratory tract infection. However, our study did not look at the effects of different modes of dosing in circumstances of loss of control of asthma; this requires further assessment. Patients with severe chronic asthma have responded better to more frequent dosing, while twice-daily FP has, however, given good results in such patients (18) .
For the definition of asthma severity, in the present study patients were classified as mild or moderate according to the physician's judgment, baseline expiratory flows and medication need. Furthermore, this study did not have a steroid withdrawal phase. Although theoretically ideal, this type of study is quite demanding and complicated, and it is associated with asthma worsening, which prolongs the study. For these reasons, a steroid withdrawal phase was not not included in this study. If most patients had been overtreated, this could have reduced the possibility of observing a difference between the two treatment regimens.
Many of the previous studies comparing once-daily and twice-daily treatment regimens of ICS have offered no clear recommendation, although in clinical practice some ICS are prescribed once daily. Most of the reported studies examined small numbers of patients. In addition, these studies were often conducted over short periods varying between four and 12 weeks, which makes it difficult to predict the outcome of use in the long term (5) (6) (7) (8) (9) (10) (11) . In fact, no long term studies with large patient numbers have been reported for fluticasone. In a 12-week study of 340 patients with mild to moderate asthma, Jones et al (10) reported that 400 µg BUD given once daily in the morning or evening was as effective as the same total daily dose given twice daily. However, in a 12-month study of 40 patients with moderate asthma, Weiner et al (16) reported that overall, twice-daily dosing of BUD was more effective than once-daily dosing and concluded that, for patients with worsening symptoms or for long term control of asthma, BUD twice daily is more effective than BUD once daily. Given these contradictory results with BUD, combined with the relatively short term results reported here with FP, further study is warranted to investigate the long term effectiveness of FP given once daily versus twice daily.
In a 12-week study, patients whose asthma was controlled on flunisolide 500 µg twice daily did not show significant changes from baseline PEF values, regardless of whether they were randomly assigned to flunisolide 500 µg twice daily, 1000 µg once daily in the morning or 1000 µg once daily in the evening (13) . Similarly, patients in the 12-month BUD study reported above did not show improvement over baseline PEF values (16) . Patients entered into the present study were also considered to have well controlled, stable asthma. Interestingly, although patients may have been taking flunisolide, FP, BDP or BUD during the baseline period, there was evidence of a significant improvement in asthma control following 12 weeks of treatment with FP, and more so with twice-daily than with once-daily administration, suggesting that these patients still had room for improvement.
Overall, FP was well tolerated in both studies. The overall incidence and types of adverse events were similar among treatment groups in each study and were not exceptional for an ICS. However, the incidence of asthma exacerbations was greater with once-daily than with twice-daily dosing. The majority of withdrawals in both treatment groups were because of failure to control asthma exacerbations. In the current studies with once-daily dosing of FP (0.2 or 0.5 mg/day), there was no evidence of a difference between the dosing regimens, for the cortisol levels, which remained essentially unchanged from entry.
CONCLUSIONS
This study has demonstrated that, while twice-daily administration of FP is generally more effective than oncedaily dosing, asthma control can be maintained with oncedaily administration in most patients with mild to moderate stable asthma. Although twice-daily dosing of FP was more effective than once-daily dosing in terms of PEF, there was no significant difference between the two treatment regimens with respect to FEV 1 .
